RU2705156C2 - Таблетки, содержащие большую дозу рукапариба - Google Patents

Таблетки, содержащие большую дозу рукапариба Download PDF

Info

Publication number
RU2705156C2
RU2705156C2 RU2017109139A RU2017109139A RU2705156C2 RU 2705156 C2 RU2705156 C2 RU 2705156C2 RU 2017109139 A RU2017109139 A RU 2017109139A RU 2017109139 A RU2017109139 A RU 2017109139A RU 2705156 C2 RU2705156 C2 RU 2705156C2
Authority
RU
Russia
Prior art keywords
tablet
active pharmaceutical
contained
pharmaceutical ingredient
range
Prior art date
Application number
RU2017109139A
Other languages
English (en)
Russian (ru)
Other versions
RU2017109139A (ru
RU2017109139A3 (enExample
Inventor
Джеффри ЭТТЕР
Original Assignee
Кловис Онколоджи, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кловис Онколоджи, Инк. filed Critical Кловис Онколоджи, Инк.
Publication of RU2017109139A publication Critical patent/RU2017109139A/ru
Publication of RU2017109139A3 publication Critical patent/RU2017109139A3/ru
Application granted granted Critical
Publication of RU2705156C2 publication Critical patent/RU2705156C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017109139A 2014-08-22 2015-08-17 Таблетки, содержащие большую дозу рукапариба RU2705156C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US62/040,849 2014-08-22
US201562101739P 2015-01-09 2015-01-09
US62/101,739 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Publications (3)

Publication Number Publication Date
RU2017109139A RU2017109139A (ru) 2018-09-24
RU2017109139A3 RU2017109139A3 (enExample) 2019-03-06
RU2705156C2 true RU2705156C2 (ru) 2019-11-05

Family

ID=55347324

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017109139A RU2705156C2 (ru) 2014-08-22 2015-08-17 Таблетки, содержащие большую дозу рукапариба

Country Status (24)

Country Link
US (3) US9987285B2 (enExample)
EP (1) EP3182975B1 (enExample)
JP (3) JP6574477B2 (enExample)
KR (2) KR102803917B1 (enExample)
CN (2) CN106794185A (enExample)
AU (2) AU2015305696B2 (enExample)
BR (1) BR112017000865A2 (enExample)
CA (1) CA2955495C (enExample)
DK (1) DK3182975T3 (enExample)
ES (1) ES3048688T3 (enExample)
FI (1) FI3182975T3 (enExample)
HR (1) HRP20251484T1 (enExample)
IL (1) IL249946B (enExample)
LT (1) LT3182975T (enExample)
MX (1) MX367260B (enExample)
NZ (1) NZ728392A (enExample)
PL (1) PL3182975T3 (enExample)
PT (1) PT3182975T (enExample)
RS (1) RS67356B1 (enExample)
RU (1) RU2705156C2 (enExample)
SG (1) SG11201700265VA (enExample)
SI (1) SI3182975T1 (enExample)
SM (1) SMT202600141T1 (enExample)
WO (1) WO2016028689A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3102564A4 (en) 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
AU2015305696B2 (en) * 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
EP3573990B1 (en) 2017-01-24 2024-07-10 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
EA201992177A1 (ru) 2017-03-27 2020-02-25 Тесаро, Инк. Композиции на основе нирапариба
AU2018341479B2 (en) * 2017-09-26 2022-02-17 Tesaro, Inc. Niraparib formulations
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
CN111989137A (zh) 2018-01-05 2020-11-24 赛博克萨1公司 用于治疗涉及酸性或缺氧性患病组织的疾病的化合物、组合物和方法
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
WO2020113500A1 (zh) * 2018-12-06 2020-06-11 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
KR20220052918A (ko) 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
PH12022550037A1 (en) 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
ES3051838T3 (en) 2020-07-14 2025-12-30 Assia Chem Ind Ltd Solid state forms of rucaparib salts
EP4188375A4 (en) 2020-07-29 2024-07-24 Allergan Pharmaceuticals International Limited MIGRAINE TREATMENT
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
AU2021409718A1 (en) 2020-12-22 2023-07-13 Allergan Pharmaceuticals International Limited Treatment of migraine
TW202304447A (zh) 2021-04-08 2023-02-01 瑞士商瑞森製藥公司 聚（ａｄｐ－核糖）聚合酶抑制劑
MX2024003952A (es) 2021-09-27 2024-05-27 Allergan Pharmaceuticals Int Ltd Combinación que comprende atogepant para tratar la migraña.
JP2024543323A (ja) * 2021-11-10 2024-11-21 クリチテック，インコーポレイテッド ルカパリブ粒子およびその使用
EP4463232A1 (en) 2022-01-11 2024-11-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110136883A1 (en) * 2008-04-09 2011-06-09 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
US20120302550A1 (en) * 2010-02-12 2012-11-29 Pfizer Inc. Salts and polymorphs of 8-fluoro-2--1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05006B1 (et) 1999-01-11 2008-04-15 Agouron Pharmaceuticals, Inc. Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid
JP2006522088A (ja) 2003-03-31 2006-09-28 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
PL1660095T3 (pl) 2003-07-25 2010-07-30 Cancer Research Tech Ltd Tricykliczne inhibitory PARP
PL1794163T3 (pl) 2004-09-22 2010-06-30 Pfizer Sposób wytwarzania inhibitorów poli(adp-rybozo)polimerazy
ATE551345T1 (de) 2004-09-22 2012-04-15 Pfizer Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
JP2008513435A (ja) 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
US20140044802A1 (en) * 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110136883A1 (en) * 2008-04-09 2011-06-09 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
US20120302550A1 (en) * 2010-02-12 2012-11-29 Pfizer Inc. Salts and polymorphs of 8-fluoro-2--1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
RU2570198C2 (ru) * 2010-02-12 2015-12-10 Пфайзер Инк. СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА

Also Published As

Publication number Publication date
HRP20251484T1 (hr) 2026-01-02
PT3182975T (pt) 2025-10-28
US20180200260A1 (en) 2018-07-19
IL249946A0 (en) 2017-03-30
US10130636B2 (en) 2018-11-20
ES3048688T3 (en) 2025-12-11
RU2017109139A (ru) 2018-09-24
MX367260B (es) 2019-08-12
US20160051561A1 (en) 2016-02-25
AU2019272064A1 (en) 2019-12-19
MX2017001540A (es) 2017-05-11
KR20170043597A (ko) 2017-04-21
WO2016028689A1 (en) 2016-02-25
EP3182975A1 (en) 2017-06-28
JP2017525712A (ja) 2017-09-07
BR112017000865A2 (pt) 2017-12-05
FI3182975T3 (fi) 2025-11-13
JP6797980B2 (ja) 2020-12-09
AU2015305696A1 (en) 2017-02-02
AU2015305696B2 (en) 2019-08-29
SMT202600141T1 (it) 2026-05-12
CA2955495A1 (en) 2016-02-25
SG11201700265VA (en) 2017-02-27
KR102803917B1 (ko) 2025-05-07
JP7127101B2 (ja) 2022-08-29
JP6574477B2 (ja) 2019-09-11
LT3182975T (lt) 2025-11-25
NZ728392A (en) 2023-06-30
CA2955495C (en) 2023-09-19
RS67356B1 (sr) 2025-11-28
RU2017109139A3 (enExample) 2019-03-06
SI3182975T1 (sl) 2025-12-31
CN106794185A (zh) 2017-05-31
US9987285B2 (en) 2018-06-05
DK3182975T3 (da) 2025-10-20
IL249946B (en) 2020-05-31
KR20230097211A (ko) 2023-06-30
US20190099430A1 (en) 2019-04-04
JP2020002149A (ja) 2020-01-09
PL3182975T3 (pl) 2026-02-23
EP3182975A4 (en) 2018-04-18
AU2019272064B2 (en) 2021-11-18
JP2021038242A (ja) 2021-03-11
EP3182975B1 (en) 2025-10-01
CN113209033A (zh) 2021-08-06

Similar Documents

Publication Publication Date Title
JP7127101B2 (ja) ルカパリブの高投与力価錠剤
RU2456989C2 (ru) Твердые лекарственные формы, содержащие тадалафил
KR100634253B1 (ko) 초강력 붕해제를 사용한 고속-용해 에파비렌즈 캡슐 또는정제 및 그의 제조 방법
KR100202154B1 (ko) 파라세타몰 및 돔페리돈을 함유한 필름 피복 정제
WO2016020080A1 (en) Pharmaceutical compositions of edoxaban
TWI418370B (zh) 溶出安定性製劑
KR20160002177A (ko) 오셀타미비어 유리염기를 포함하는 약학 조성물
JP2016539110A (ja) イソニアジドの顆粒およびリファペンチンの顆粒を含む分散性錠剤の形態の抗結核性の安定な医薬組成物ならびにその製造方法
JP7336528B2 (ja) ネフォパムおよびアセトアミノフェンを含む薬学的組成物の製造方法、およびそれによって得られる薬学的組成物
KR102102462B1 (ko) 오셀타미비어 유리염기를 포함하는 약학 조성물
EP3079672B1 (en) Pharmaceutical composition comprising a pharmaceutically acceptable salt of rasagiline
WO2019206472A1 (en) Tablet compositions comprising abiraterone acetate
EP4401708A1 (en) Pharmaceutical composition of bempedoic acid
EA051960B1 (ru) Фармацевтическая композиция бемпедоевой кислоты
HK1232807A1 (en) High dosage strength tablets of rucaparib
HK1232807B (en) High dosage strength tablets of rucaparib
EP3272348A1 (en) Pharmaceutical composition comprising idelalisib